We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Regeneron Pharmaceuticals
REGN
$71.2B
| $10.9M | 9.4% |
31,354
-1,805
| -5% | -$695K |
|
|
2
PUT
Regeneron Pharmaceuticals
REGN
$71.2B
| $7.58M | 6.51% |
47,000
-1,500
| -3% | -$578K |
|
|
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
| $7.18M | 6.17% |
119,135
+80,980
| +212% | +$4.59M |
|
4
Abbott
ABT
$172B
| $5M | 4.3% |
127,252
-8,048
| -6% | -$320K |
|
|
5
Cal-Maine
CALM
$4.18B
| $3.64M | 3.12% |
82,081
+59,189
| +259% | +$2.79M |
|
|
6
Biogen
BIIB
$30.8B
| $3.54M | 3.04% |
14,632
+13,516
| +1,211% | +$3.56M |
|
|
OTIC
7
DELISTED
Otonomy, Inc.
OTIC
| $3.06M | 2.63% |
192,785
+36,348
| +23% | +$542K |
|
|
8
Apple
AAPL
$4.89T
| $2.76M | 2.37% |
115,376
+93,948
| +438% | +$2.33M |
|
9
Akebia Therapeutics
AKBA
$376M
| $2.75M | 2.36% |
367,276
-22,643
| -6% | -$198K |
|
|
10
Bristol-Myers Squibb
BMY
$124B
| $2.58M | 2.22% |
+35,075
| New | +$2.48M |
|
|
ALR
11
DELISTED
Alere Inc
ALR
| $2.22M | 1.9% |
53,163
+17,000
| +47% | +$738K |
|
|
ICPT
12
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.81M | 1.56% |
12,900
| – | – |
|
13
BioMarin Pharmaceuticals
BMRN
$11.6B
| $1.66M | 1.43% |
+21,373
| New | +$1.82M |
|
|
POT
14
DELISTED
Potash Corp Of Saskatchewan
POT
| $1.56M | 1.34% |
96,080
+36,080
| +60% | +$604K |
|
15
PUT
Bausch Health
BHC
$1.84B
| $1.54M | 1.33% |
50,700
-84,400
| -62% | -$2.39M |
|
|
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $1.54M | 1.32% |
10,779
-4,535
| -30% | -$661K |
|
|
GWPH
17
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $1.53M | 1.32% |
129,800
+52,800
| +69% | +$4.44M |
|
18
Humana
HUM
$46.4B
| $1.41M | 1.21% |
7,850
+1,272
| +19% | +$226K |
|
|
LUMO
19
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $1.29M | 1.11% |
2,433
+211
| +9% | +$26.2K |
|
20
Sarepta Therapeutics
SRPT
$1.82B
| $1.16M | 1% |
+60,908
| New | +$1.13M |
|
|
YHOO
21
DELISTED
Yahoo Inc
YHOO
| $1.14M | 0.98% |
30,341
+25,100
| +479% | +$926K |
|
22
Rocket Pharmaceuticals
RCKT
$372M
| $1.08M | 0.93% |
36,188
-6,200
| -15% | -$218K |
|
|
23
PUT
Biogen
BIIB
$30.8B
| $1.07M | 0.92% |
25,000
+10,000
| +67% | +$2.64M |
|
|
CASC
24
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $1.05M | 0.91% |
186,277
+17,009
| +10% | +$115K |
|
25
Johnson & Johnson
JNJ
$602B
| $1.04M | 0.9% |
+8,606
| New | +$978K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.